December 21, 2017 / 1:07 PM / 9 months ago

BRIEF-Altimmune Announces Positive Initial Data From Its Heptcell Phase 1 Study

Dec 21 (Reuters) - Altimmune Inc:

* ALTIMMUNE ANNOUNCES POSITIVE INITIAL DATA FROM ITS HEPTCELL PHASE 1 STUDY

* ALTIMMUNE INC - HAS COMPLETED DOSING OF ITS HEPTCELL PHASE 1 STUDY IN CHRONIC HEPATITIS B

* ALTIMMUNE INC - ALL DOSES WERE WELL TOLERATED, THERE WERE NO HEPATIC FLARES, AND NO DISCONTINUATIONS IN STUDY

* ALTIMMUNE INC - LABORATORY ANALYSIS IS ONGOING AND FULL ANALYSIS OF ALL DATA THROUGH POST DOSING PERIOD WILL BE AVAILABLE Q1 2018

* ALTIMMUNE INC - PRELIMINARY DATA SHOWED EVIDENCE OF DOSE DEPENDENT INCREASES IN CELLULAR IMMUNE RESPONSE TO HBV ANTIGENS IN STUDY Source text for Eikon: Further company coverage: (Bangalore.newsroom@thomsonreuters.com)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below